Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. | Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma A retrospective study